Suppr超能文献

恢复期血浆疗法治疗新型冠状病毒肺炎的有效性:一项循证病例报告

Effectiveness of Convalescent Plasma Therapy in Treating COVID-19: an Evidence-based Case Report.

作者信息

Yulianti Mira, Johan Christian, Singh Gurmeet, Tenda Eric Daniel, Herikurniawan Herikurniawan, Wijaya I Putu Eka Krisnha

机构信息

Division of Respirology and Critical Illness, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.

出版信息

Acta Med Indones. 2021 Oct;53(4):497-504.

Abstract

BACKGROUND

Convalescent plasma is a potentially beneficial, tolerable, and available additional treatment option for COVID-19. This study aims to evaluate whether the administration of convalescent plasma therapy leads to improved clinical outcomes in COVID-19 patients compared to standard medical therapy.

METHODS

We conducted a search of Pubmed, Cochrane, and EBSCO for studies assessing the clinical question using inclusion and exclusion criteria. Selected studies were critically appraised, and the results were summarized.

RESULTS

A meta-analysis of 10 randomized clinical trials (RCTs), an RCT, a case-control clinical study were selected and assessed. Only the case-control clinical study showed that convalescent plasma administration improved the clinical outcomes of patients with COVID-19, including all-cause mortality, hospital length of stay, and the need for mechanical ventilation. On the contrary, the other two studies of a higher level of evidence showed no significant clinical outcome improvement with convalescent plasma therapy.

CONCLUSION

The effectiveness of convalescent plasma therapy in improving clinical outcomes of patients with COVID-19 was still inconclusive due to several study limitations and other possible causes.

摘要

背景

恢复期血浆是一种对新型冠状病毒肺炎(COVID-19)可能有益、可耐受且可获得的额外治疗选择。本研究旨在评估与标准药物治疗相比,给予恢复期血浆治疗是否能改善COVID-19患者的临床结局。

方法

我们在PubMed、Cochrane和EBSCO中进行检索,以纳入和排除标准评估有关该临床问题的研究。对选定的研究进行严格评价,并总结结果。

结果

选择并评估了10项随机临床试验(RCT)的荟萃分析、1项RCT和1项病例对照临床研究。只有病例对照临床研究表明,给予恢复期血浆可改善COVID-19患者的临床结局,包括全因死亡率、住院时间和机械通气需求。相反,另外两项证据水平较高的研究表明,恢复期血浆治疗并未显著改善临床结局。

结论

由于若干研究局限性和其他可能原因,恢复期血浆治疗改善COVID-19患者临床结局的有效性仍不明确。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验